Drug Approval | April 22, 2024
Lupin launches Mirabegron Extended-Release Tablets in US
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
The product is expected to be launched by Q4 FY23.
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
The company has 47 ANDA's pending approval with the U.S.FDA
Subscribe To Our Newsletter & Stay Updated
